KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation and Depletion (2017 - 2018)

Historic Depreciation and Depletion for Amneal Pharmaceuticals (AMRX) over the last 2 years, with Q4 2018 value amounting to $18.6 million.

  • Amneal Pharmaceuticals' Depreciation and Depletion rose 5618.76% to $18.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $63.3 million, marking a year-over-year change of. This contributed to the annual value of $62.6 million for FY2024, which is 543.81% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Depreciation and Depletion of $18.6 million as of Q4 2018, which was up 5618.76% from $17.4 million recorded in Q3 2018.
  • Amneal Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $18.6 million during Q4 2018, with a 5-year trough of $9.6 million in Q2 2017.